About Anika Therapeutics (NASDAQ:ANIK)
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: Health Care Supplies
- Symbol: NASDAQ:ANIK
- CUSIP: 03525510
- Web: www.anikatherapeutics.com
Capitalization:- Market Cap: $875.84 million
- Outstanding Shares: 14,658,000
Average Prices:- 50 Day Moving Avg: $57.54
- 200 Day Moving Avg: $50.30
- 52 Week Range: $41.38 - $60.27
P/E:- Trailing P/E Ratio: 26.57
- Foreward P/E Ratio: 35.39
- P/E Growth: 2.73
Sales & Book Value:- Annual Revenue: $111.36 million
- Price / Sales: 7.87
- Book Value: $16.66 per share
- Price / Book: 3.59
Profitability:- EBITDA: $56.02 million
- Net Margins: 30.44%
- Return on Equity: 14.88%
- Return on Assets: 13.78%
Debt:- Current Ratio: 14.35%
- Quick Ratio: 13.04%
Misc:- Average Volume: 89,905 shs.
- Beta: 1.66
- Short Ratio: 14.7
Frequently Asked Questions for Anika Therapeutics (NASDAQ:ANIK)
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc. (NASDAQ:ANIK) posted its earnings results on Wednesday, July, 26th. The company reported $0.76 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.44 by $0.32. The company earned $33.50 million during the quarter, compared to analysts' expectations of $27.20 million. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. Anika Therapeutics's quarterly revenue was up 25.9% on a year-over-year basis. During the same period last year, the company posted $0.57 earnings per share. View Anika Therapeutics' Earnings History.
When will Anika Therapeutics make its next earnings announcement?
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Syndax Pharmaceuticals (SNDX), Mirna Therapeutics (SYBX), Strongbridge Biopharma PLC (SBBP), Mereo BioPharma Group PLC (MPH), Fortress Biotech (FBIO), Peregrine Pharmaceuticals (PPHM), Kadmon Holdings (KDMN), Kamada (KMDA), Vericel Corporation (VCEL), MediWound (MDWD), Alimera Sciences (ALIM), KalVista Pharmaceuticals (KALV), VIVUS (VVUS) and Opiant Pharmaceuticals (OPNT).
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Joseph G. Darling, President
- Charles H. Sherwood Ph.D., Chief Executive Officer, Director
- Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary
- Dana M. Alexander, Chief Operating Officer
- Edward Ahn Ph.D., Chief Technology and Strategy Officer
- Richard Hague, Chief Commercial Officer
- Joseph Lyon Bower Ph.D., Lead Independent Director
- Raymond J. Land, Independent Director
- Glenn R. Larsen Ph.D., Independent Director
- Jeffrey S. Thompson, Independent Director
Who owns Anika Therapeutics stock?
Anika Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
(11.49%), Fisher Asset Management LLC (0.72%) and Eqis Capital Management Inc. (0.28%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Raymond J Land. View Institutional Ownership Trends for Anika Therapeutics.
Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?
How do I buy Anika Therapeutics stock?
Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of Anika Therapeutics stock can currently be purchased for approximately $59.81.
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Consensus Price Target History for Anika Therapeutics (NASDAQ:ANIK)
Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/27/2016 | Northland Securities | Downgrade | Outperform -> Market Perform | | N/A |  |
| 2/26/2016 | Barrington Research | Boost Price Target | Outperform | $45.00 -> $49.00 | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for Anika Therapeutics (NASDAQ:ANIK)Earnings History by Quarter for Anika Therapeutics (NASDAQ ANIK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | $0.44 | | | | | N/A | |
| 7/26/2017 | Q2 2017 | $0.44 | $0.76 | $27.20 million | $33.50 million | View | N/A | |
| 5/3/2017 | Q1 2017 | $0.38 | $0.37 | $23.89 million | $23.39 million | View | Listen | |
| 2/15/2017 | Q416 | $0.53 | $0.54 | $27.84 million | $28.70 million | View | N/A | |
| 10/26/2016 | Q316 | $0.47 | $0.59 | $26.60 million | $25.79 million | View | Listen | |
| 7/27/2016 | Q216 | $0.44 | $0.57 | $24.75 million | $26.60 million | View | Listen | |
| 4/27/2016 | Q116 | $0.28 | $0.45 | $19.26 million | $22.30 million | View | Listen | |
| 2/24/2016 | Q415 | $0.60 | $0.72 | $28.19 million | $25.60 million | View | Listen | |
| 10/28/2015 | Q315 | $0.34 | $0.55 | $22.36 million | $23.70 million | View | Listen | |
| 7/29/2015 | Q215 | $0.34 | $0.51 | $21.65 million | $22.90 million | View | Listen | |
| 4/28/2015 | Q115 | $0.21 | $0.23 | $16.20 million | $15.50 million | View | Listen | |
| 2/25/2015 | Q414 | $0.48 | $0.51 | $24.60 million | $23.30 million | View | Listen | |
| 10/29/2014 | Q314 | $0.33 | $0.40 | $20.33 million | $22.10 million | View | Listen | |
| 7/30/2014 | Q214 | $0.57 | $0.60 | $28.20 million | $26.27 million | View | Listen | |
| 4/29/2014 | Q114 | $0.25 | $0.97 | $16.03 million | $34.00 million | View | N/A | |
| 2/26/2014 | Q413 | $0.42 | $0.44 | $21.91 million | $21.30 million | View | Listen | |
| 10/31/2013 | Q313 | $0.14 | $0.33 | $16.96 million | $17.80 million | View | Listen | |
| 7/31/2013 | Q2 2013 | $0.25 | $0.40 | $17.09 million | $20.80 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)2017 EPS Consensus Estimate: $1.85
2018 EPS Consensus Estimate: $1.75
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.34 | $0.42 | $0.38 |
| Q2 2017 | 2 | $0.42 | $0.47 | $0.45 |
| Q3 2017 | 2 | $0.39 | $0.42 | $0.41 |
| Q4 2017 | 2 | $0.62 | $0.62 | $0.62 |
| Q1 2018 | 2 | $0.32 | $0.36 | $0.34 |
| Q2 2018 | 1 | $0.47 | $0.47 | $0.47 |
| Q3 2018 | 1 | $0.44 | $0.44 | $0.44 |
| Q4 2018 | 1 | $0.50 | $0.50 | $0.50 |
(Data provided by Zacks Investment Research)
Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Anika Therapeutics (NASDAQ:ANIK)Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 84.32%
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/16/2017 | Charles H Sherwood | CEO | Sell | 3,293 | $60.04 | $197,711.72 | |
| 10/13/2017 | Charles H Sherwood | CEO | Sell | 7,124 | $60.08 | $428,009.92 | |
| 7/27/2017 | Charles H Sherwood | CEO | Sell | 63,799 | $50.79 | $3,240,351.21 | |
| 7/5/2017 | Charles H Sherwood | CEO | Sell | 14,201 | $50.03 | $710,476.03 | |
| 5/22/2017 | Jeffery S Thompson | Director | Sell | 10,725 | $47.39 | $508,257.75 | |
| 11/9/2016 | Joseph I Bower | Director | Sell | 540 | $43.39 | $23,430.60 | |
| 2/25/2016 | Raymond J Land | Director | Sell | 2,695 | $43.62 | $117,555.90 | |
| 2/27/2015 | Raymond J Land | Director | Sell | 4,621 | $39.49 | $182,483.29 | |
| 5/1/2014 | Charles H Sherwood | CEO | Sell | 83,780 | $44.32 | $3,713,129.60 | |
| 2/28/2014 | Charles H Sherwood | CEO | Sell | 200,000 | $41.70 | $8,340,000.00 | |
| 8/22/2013 | John C Moran | Director | Sell | 5,000 | $24.35 | $121,750.00 | |
| 8/8/2013 | Steve E Wheeler | Director | Sell | 26,984 | $23.61 | $637,092.24 | |
| 8/7/2013 | Steve E Wheeler | Director | Sell | 11,016 | $27.01 | $297,542.16 | |
| 8/6/2013 | Farmaceutici S.P.A. Fidia | Major Shareholder | Sell | 1,270,000 | $24.52 | $31,140,400.00 | |
| 7/15/2013 | Charles H Sherwood | CEO | Sell | 75,000 | $20.11 | $1,508,250.00 | |
| 7/9/2013 | Charles H Sherwood | CEO | Sell | 49,185 | $18.06 | $888,281.10 | |
| 7/5/2013 | Charles H Sherwood | CEO | Sell | 34,662 | $18.01 | $624,262.62 | |
| 6/19/2013 | Charles H Sherwood | CEO | Sell | 1,847 | $18.00 | $33,246.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Anika Therapeutics (NASDAQ:ANIK)
Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
| Source: |
|
| Date | Headline |
|---|
 | Insider Selling: Anika Therapeutics Inc. (ANIK) CEO Sells 3,293 Shares of Stock
www.americanbankingnews.com - October 18 at 8:10 PM |
 | ETFs with exposure to Anika Therapeutics, Inc. : October 18, 2017
finance.yahoo.com - October 18 at 5:09 PM |
| Anika Therapeutics Inc. (ANIK) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 2:16 AM |
 | ANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For Opdivo
www.rttnews.com - October 17 at 4:46 PM |
 | Anika Therapeutics (ANIK) Reports Regulatory Approval for MONOVISC in Australia
www.streetinsider.com - October 17 at 4:46 PM |
| Insider Selling: Anika Therapeutics Inc. (ANIK) CEO Sells 7,124 Shares of Stock
www.americanbankingnews.com - October 16 at 7:40 PM |
| Anika Announces Regulatory Approval for MONOVISC® in Australia for the Treatment of Pain Associated with Osteoarthritis of all Synovial Joints
finance.yahoo.com - October 16 at 4:44 PM |
| Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25
finance.yahoo.com - October 11 at 5:26 PM |
| Anika Therapeutics Inc. (ANIK) Given $53.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - October 9 at 2:26 AM |
| Analyzing Anika Therapeutics (ANIK) & Its Peers
www.americanbankingnews.com - October 3 at 6:20 PM |
 | Viscosupplementation Market By Product, By Region And Segment Forecasts, 2014 - 2025
www.prnewswire.com - September 22 at 1:37 PM |
| Head-To-Head Survey: Anika Therapeutics (ANIK) versus Its Peers
www.americanbankingnews.com - September 16 at 6:30 PM |
 | Viscosupplementation Market Worth $6.52 Billion by 2025: Grand View Research, Inc.
www.finanznachrichten.de - September 4 at 4:25 PM |
| Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
finance.yahoo.com - August 28 at 9:02 PM |
| Analyzing Anika Therapeutics (ANIK) and Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - August 26 at 12:22 AM |
| Anika (ANIK) Grows in Orthopedic Medicines on Positive Data
finance.yahoo.com - August 15 at 4:52 PM |
| ETFs with exposure to Anika Therapeutics, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 4:52 PM |
| Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee
finance.yahoo.com - August 7 at 4:46 PM |
 | Nine Chapters Capital Management LLC Buys Pattern Energy Group Inc, Constellation Brands Inc, ...
www.nasdaq.com - August 1 at 9:52 PM |
| Anika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017
finance.yahoo.com - August 1 at 4:51 PM |
| Insider Selling: Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Sells 63,799 Shares of Stock
www.americanbankingnews.com - July 31 at 7:29 PM |
| Head to Head Contrast: Tokai Pharmaceuticals (NVUS) and Anika Therapeutics (ANIK)
www.americanbankingnews.com - July 28 at 12:33 PM |
| Gainers & Losers Of July 27: CAPR, ANIK, MMSI, AZN, TTPH, AGEN...
www.finanznachrichten.de - July 28 at 1:43 AM |
| Edited Transcript of ANIK earnings conference call or presentation 27-Jul-17 1:00pm GMT
finance.yahoo.com - July 28 at 1:43 AM |
| Anika Announces Appointment of Joseph Darling as President
finance.yahoo.com - July 27 at 3:35 PM |
| Anika Therapeutics Inc. (NASDAQ:ANIK) Issues Earnings Results
www.americanbankingnews.com - July 27 at 12:39 PM |
| Anika posts 2Q profit
finance.yahoo.com - July 26 at 9:28 PM |
| Anika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : July 26, 2017
finance.yahoo.com - July 26 at 4:27 PM |
| Anika Reports Strong Second Quarter 2017 Financial Results
finance.yahoo.com - July 26 at 4:27 PM |
| Anika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated with Osteoarthritis of All Synovial Joints
finance.yahoo.com - July 24 at 6:15 PM |
| Critical Analysis: Anika Therapeutics (NASDAQ:ANIK) & KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - July 24 at 4:06 PM |
| Anika Therapeutics Inc. (ANIK) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - July 18 at 8:16 AM |
 | BRIEF-Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc
www.reuters.com - July 17 at 9:19 PM |
| Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
finance.yahoo.com - July 17 at 4:16 PM |
| Anika pays former medical chief $350K to thwart possible lawsuit
finance.yahoo.com - July 17 at 12:36 PM |
 | Anika Therapeutics (ANIK) Presents At Singular Summer Solstice Conference - Slideshow
seekingalpha.com - July 13 at 4:39 PM |
| Anika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : July 12, 2017
finance.yahoo.com - July 12 at 4:24 PM |
| Anika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26
finance.yahoo.com - July 12 at 4:24 PM |
| Anika Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ANIK-US : July 11, 2017
finance.yahoo.com - July 11 at 5:08 PM |
| New Strong Sell Stocks for July 11th
finance.yahoo.com - July 11 at 5:07 PM |
| ETFs with exposure to Anika Therapeutics, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 5:07 PM |
| Research Analysts Offer Predictions for Anika Therapeutics Inc.'s Q2 2017 Earnings (ANIK)
www.americanbankingnews.com - July 10 at 7:36 AM |
| Charles H. Sherwood Sells 14,201 Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) Stock
www.americanbankingnews.com - July 6 at 7:22 PM |
| Anika to Present at the Singular Research Summer Solstice Conference on July 13, 2017
finance.yahoo.com - July 6 at 5:10 PM |
| Facial Injectables Market to Reach $17.2 Billion by 2025 - Fueled by Advancements in Facial Rejuvenation Procedures - Research and Markets
www.finanznachrichten.de - June 24 at 2:12 AM |
| Facial Injectables Market is expected to reach USD 17.2 billion by 2025
www.prnewswire.com - June 20 at 9:09 PM |
 | Facial Injectables Market Size Worth $17.2 Billion By 2025: Grand View Research, Inc.
www.marketwatch.com - June 13 at 1:04 PM |
| Anika Therapeutics Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 7 at 11:29 AM |
 | Global Hyaluranoic Acid Raw Material Market expected to be worth 7.25 Billion USD by 2024
www.bizjournals.com - May 3 at 9:31 AM |
| 6 Companies That Offer Strong Value Potential for 2nd-Quarter 2017 - Nasdaq
www.nasdaq.com - March 31 at 8:45 PM |
Anika Therapeutics (ANIK) Chart for Saturday, October, 21, 2017
